Country: United States
Language: English
Source: NLM (National Library of Medicine)
APOMORPHINE HYDROCHLORIDE (UNII: F39049Y068) (APOMORPHINE - UNII:N21FAR7B4S)
Tercica, Inc.
APOMORPHINE HYDROCHLORIDE
APOMORPHINE HYDROCHLORIDE 30 mg in 3 mL
PRESCRIPTION DRUG
New Drug Application
APOKYN- APOMORPHINE HYDROCHLORIDE INJECTION TERCICA, INC. ---------- APOKYN APOMORPHINE HYDROCHLORIDE INJECTION 10 MG/ML FOR SUBCUTANEOUS USE ONLY NOT FOR IV USE RX ONLY DESCRIPTION APOKYN (apomorphine hydrochloride, USP) is a non-ergoline dopamine agonist. Apomorphine hydrochloride is chemically designated as 6aβ-Aporphine-10,11-diol hydrochloride hemihydrate with a molecular formula of C H NO • HCl • 1/2H O. Its structural formula and molecular weight are: M.W. 312.79 Apomorphine hydrochloride appears as minute, white or grayish-white glistening crystals or as white powder that is soluble in water at 80°C. APOKYN 10 mg/mL is a clear, colorless, sterile solution for subcutaneous injection and is available in 3 mL cartridges. Each mL of solution contains 10 mg of apomorphine hydrochloride, USP as apomorphine hydrochloride hemihydrate and 1 mg of sodium metabisulfite, NF in water for injection, USP. In addition, each mL of solution may contain sodium hydroxide, NF and/or hydrochloric acid, NF to adjust the pH of the solution and 5 mg/mL of benzyl alcohol, NF as a preservative. CLINICAL PHARMACOLOGY MECHANISM OF ACTION: APOKYN is a non-ergoline dopamine agonist with high _in vitro _binding affinity for the dopamine D receptor (K = 4.4 nM), moderate affinity for the dopamine D , D , and D (K = 35-83, 26, and 15 nM, respectively), and adrenergic α , α , α (K = 65, 66, and 36 nM, respectively) receptors, and low affinity for the dopamine D , serotonin 5HT , 5HT , 5HT , and 5HT (K = 370, 120, 120, 130, and 100 nM, respectively) receptors. Apomorphine exhibits no affinity for the adrenergic β and β or histamine H receptors (K > 10,000 nM). The precise mechanism of action of APOKYN as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D - type receptors within the caudate-putamen in the brain. Apomorphine has been shown to improve motor function in an animal model of Parkinson’s disease. In particular, apomorphine attenuates the motor Read the complete document